Copyright Emory Healthcare 2014 All Rights Reserved.
|
|
- Alexandra Stevens
- 5 years ago
- Views:
Transcription
1 This document is provided as a courtesy to those interested in Emory Healthcare and does not constitute medical or any other advice and does not create any physician-patient relationship. Also, Emory Healthcare does not endorse or recommend any specific commercial product or service. This document is provided solely for informational purposes only and no part of it may be used for any other purpose. The Emory Healthcare Ebola Preparedness Protocols full site/materials Disclaimer is available at These documents are subject to change based on developing epidemiology in the country. Updated 11/10/ :34 AM Copyright Emory Healthcare 2014 All Rights Reserved.
2 Care of the Patient with Ebola Virus Disease EBOLA VIRUS DISEASE (EVD)
3 Background on Ebola Virus Family Filoviridae Two genera: marburgvirus and ebolavirus Enveloped RNA virus Five subtypes of Ebola virus Zaire (EBOV) Sudan (SUDV) Tai Forest (TAFV) Bundibugyo (BDBV) Reston (RESTV) Mortality from Ebola virus disease (EVD) historically has ranged from 40-88% Cynthia Goldsmith/CDC
4 Ebola Transmission Zoonotic infection Natural reservoir is likely the fruit bat Can be transmitted to other mammals, including primates Human acquisition contact with infected animal, then human-human
5 Human to Human Transmission Ebola is present in blood and body fluids of symptomatic patients Ebola is spread through direct contact of mucous membranes or broken skin with: Blood or body fluids urine, saliva, feces, and vomit Contaminated objects (like needles and syringes) Deceased human victims High amount of viral release after death More infectious as patient becomes more ill
6 Current Outbreak Totals 13,733 cases and 4,920 deaths (as of October 31, 2014) Guinea 1,906 cases 997 deaths Sierra Leone 5,235 cases 1,500 deaths Liberia 6,535 cases 2,413 deaths Nigeria, Senegal, Spain, Mali and USA: 27 cases; 10 deaths
7 Clinical Characteristics of EVD Acute infection starts as a non-specific febrile illness Fever, severe headache, muscle pain, malaise Progression to include GI symptoms diarrhea and vomiting May appear 2-21 days after exposure 8-10 days most common Courtesy of Pierre Rollin, CDC
8 Clinical Characteristics of EVD Small vessel involvement Increased permeability due to cellular damage Multi-organ system failure Hypovolemia Electrolyte derangements Hemorrhage may develop in the second week Coagulopathies Disseminated intravascular coagulation (DIC) Poor prognosis associated with Shock, encephalopathy, extensive hemorrhage
9 Clinical Course of EVD Prodromal phase day 1-3 Fever, malaise/fatigue, headache, myalgias Leukopenia (esp lymphopenia) & thrombocytopenia Limited viral shedding Fever Myalgias Chills Headache Sore throat Abdominal pain Diarrhea Vomiting Rash Bleeding MOF/Death
10 Clinical Course of EVD Fever + Gastroenteritis/hepatitis day 3-4 to 8-12 Vomiting, diarrhea volume depletion, electrolyte loss Metabolic acidosis Elevated AST > ALT but minimal hyperbilirubinemia Fever Myalgias Chills Headache Sore throat Abdominal pain Diarrhea Vomiting Rash Bleeding MOF/Death
11 Critical Illness in EVD Respiratory distress/failure Renal Failure Encephalopathy Severe Shock Severe Hemorrhage Fever Myalgias Chills Headache Sore throat Abdominal pain Diarrhea Vomiting Rash Bleeding MOF/Death
12 Care of the Patient with Ebola Virus Disease LESSONS LEARNED AT EMORY
13 The Patients July 30 SCDU team informed that Emory would receive an aid worker from Liberia with EVD First week of August two were transferred by air ambulance to our hospital, 3 days apart 33 yo male physician, day 11 of illness at arrival 59 yo female missionary, day 15 of illness at arrival Received two additional patients Evacuated physician from Sierra Leone in early September Nurse transferred from a Dallas hospital in mid October
14 This type of facility is NOT necessary for the care of patients with Ebola 14
15 Clinical Care = Supportive Care No proven therapeutics Unclear availability of any experimental agents Limited safety or efficacy data in humans BUT, we received SIGNIFICANT support and advice from CDC, FDA, and medical and scientific colleagues throughout the world
16 Experimental Therapies Therapy Mechanism Status Convalescent plasma Provide anti-ebov antibodies Studies have not shown a clear benefit Has been used in multiple evacuated patients in Hyperimmune globulin from immunized animals or previously infected humans Concentrated plasma to provide high titers of neutralizing antibody this outbreak Not currently available. Work in horses and cattle are underway ZMapp (Mapp Biopharmaceutical Inc.) Cocktail of three chimeric mouse human monoclonal antibodies targeting the GP envelope protein Very promising data in macaques No human trials Very limited supply TKM Lipid (TKM-Ebola; Tekmira) Nanoparticle Small interfering Ribonucleic acid (sirna) Targets two essential viral genes to stop the virus from replicating single-dose phase 1 study in healthy volunteers found side effects including headache, dizziness, chest tightness and raised heart rate at high doses. A limited number of treatment courses
17 Experimental Therapies Therapy Mechanism Status AVI 7537 (Sarepta) Phosphorodiamidate oligonucleotide Monkey studies showed 60-80% when given at the time of infection Tolerability has been demonstrated in early studies. No human grade availability until late October Favipiravir/T-705 (Toyama Chemical/ Fuji Film) BCX4430 (Biocryst) Brincidofovir (CMX001) (Chimerix) Selective inhibition of viral RNAdependent RNA polymerase Does not inhibit RNA or DNA synthesis in mammalian cells lipid conjugate of the nucleotide analog, cidofovir (CDV) uses endogenous lipid uptake pathways to achieve high intracellular concentrations Effective against EVD in mice, but in animal monkey study only 1/6 survived Approved in Japan for influenza treatment under special circumstances. ~ treatment courses may available % survival in rodents with EVD Effective in animals 48 hours after infection with the lethal Marburg virus Testing for EVD in monkeys is underway In vitro data at CDC showing good anti-ebov activity Has been used in 4 patients
18 Experimental Therapies Therapy Mechanism Status Chimpanzee adenovirus serotype 3 (ChAd3) vaccine Uses a chimpanzee adenovirus that does not grow Contains the gene for EVD surface protein 16/16 monkeys were protected from a lethal dose by a single dose of the vaccine Trials in humans ongoing Approximately doses might be available by the end of 2014 Recombinant Vesicular Stomatitis Virus (rvsv) vaccine Recombinant VSV vector expressing ebola GP protein to induce EBOV-specific immune responses 20/ 20 monkeys protected from a lethal dose of EVD Animals with weakened immunity were not harmed by rvsv-evd Unknown if rvsv-evd will grow in humans, which would affect immunogenicity and safety Phase 1 trials underway ~800 doses available
19 The Critical Role of Nursing The ability to provide high-level nursing care and supportive care made a significant impact 24/7 one-on-one nurses allowed for rapid response to changes and adjustment of care Ability to support patients in nutrition, physical therapy, and self care Emotional support Family support Patient- and Family-Centered Model of Care
20 The Impact of Electrolytes Our patients had MARKED electrolyte abnormalities and nutritional deficiencies Hypokalemia, hypocalcemia and hyponatremia Required both intravenous and oral replacement Used oral nutritional supplements including nutritional drinks high in easily absorbed proteins, minerals and vitamins Laboratory testing for chemistries was critical to provide supportive care
21 Antibody Titer (1:x) Monitoring Virologic Status With the help of the CDC, we monitored ebola in blood Progressive declines in viral loads that correlated with improvements in clinical condition Had very low level of nucleic acid detection for several days despite resolution of ZMAPP symptoms ZMAPP 7200 dose #2 Dose # EBOV qrt-pcr (Ct value) IgM IgG NP IgG PCR CT Day of Illness Temp (C) Diarrhea
22 Conclusions from our experience Patients with Ebola can be safely cared for in our healthcare system We do expect a lower mortality rate than in underdeveloped healthcare systems Much can be learned about patient management that can be fed back to facilities with lesser levels of infrastructure Communication is critical Comprehensive, multidisciplinary patient- and familycentered models of care can be delivered even in extreme circumstances
FREQUENTLY ASKED QUESTIONS ABOUT EBOLA VIRUS DISEASE
FREQUENTLY ASKED QUESTIONS ABOUT EBOLA VIRUS DISEASE What is EBOLA? Ebola, previously known as Ebola hemorrhagic fever, is a deadly disease caused by infection with one of the Ebola virus strains. One
More informationFrequently Asked Questions About Ebola Virus Disease
Frequently Asked Questions About Ebola Virus Disease Note that many of the answers below are accurate at an identified point in time. For the most recent information, please visit www.cdc.gov/vhf/ebola.
More informationEbola Virus Disease: The Future Challenge and Promise of Providing Safe Quality Care
Ebola Virus Disease: The Future Challenge and Promise of Providing Safe Quality Care Daniel Bausch, MD, MPH&TM Technical Lead Epidemic Clinical Management Team WHO Geneva 6 th FIDSSA Congress 2015 Drakensberg,
More informationEbola, Emergency Medicine, and Global Bioethics
Ebola, Emergency Medicine, and Global Bioethics Sarah M Winston Bush, MD Assistant Professor University of Cincinnati Department of Emergency Medicine A look at the medicine What does Ebola look like High
More informationClinical Case Management Guidelines of Ebola Virus Disease (EVD)
Clinical Case Management Guidelines of Ebola Virus Disease (EVD) 1. Introduction Ebola Virus Disease (earlier known as Ebola hemorrhagic fever) is a severe, often fatal disease in humans and nonhuman primates
More informationIntervention Options against Ebola. Experience and Outlook
Intervention Options against Ebola Experience and Outlook Micha Nübling, 20 May 2015 Ebola epidemiological curve Guinea Sierra Leone Liberia 2 New and total confirmed Ebola cases Week 13.05.2015: 9 cases
More informationPrimary Care Guideline for the Management of People Concerned About/Potentially Exposed to Ebola. Provincial Ebola Response Task Force Nov.
Primary Care Guideline for the Management of People Concerned About/Potentially Exposed to Ebola Provincial Ebola Response Task Force Nov. 6, 2014 Primary Care Guidelines for the Management of People Concerned
More informationEbola therapy protects severely ill monkeys
Propojení výuky oborů Molekulární a buněčné biologie a Ochrany a tvorby životního prostředí OPVK (CZ.1.07/2.2.00/28.0032) Ebola therapy protects severely ill monkeys Nature 514, 41 43 2 October 2014 Published
More informationEbola Frequently Asked Questions
Oklahoma State Department of Health Acute Disease Service Public Health Fact Sheet Ebola Frequently Asked Questions What is Ebola Virus Disease? Ebola Virus Disease (EVD) is also called Ebola Hemorrhagic
More informationDISASTER A total of 2,615 Ebola infections and 1,427 deaths highest case fatality rates of any human virus, 88%
DISASTER A total of 2,615 Ebola infections and 1,427 deaths highest case fatality rates of any human virus, 88% ETYMOLOGY First recorded outbreak at,yambuku in democratic republic of congo (EBOLA RIVER)
More informationEbola Facts. October 14, 2014
Ebola Facts October 14, 2014 Symptoms of Ebola Initial symptoms are nonspecific - may include fever, chills, myalgias, and malaise. Patients can progress to develop gastrointestinal symptoms: severe watery
More informationIntroduction to Lassa fever
Introduction to Lassa fever Managing infectious hazards Store food in containers with lids OpenWHO.org WHO2017 1 Learning objectives Describe signs, symptoms, and transmission of Lassa fever List 4 preventive
More informationEbola Virus Disease Update. MSDH Office of Epidemiology October 15, 2014
Ebola Virus Disease Update MSDH Office of Epidemiology October 15, 2014 1 EBOLA VIRUS A hemorrhagic fever virus native to Africa with bats serving as the likely reservoir. Transmission events to humans
More informationMarburg and Ebola viruses. Stephan Becker Philipps-Universität Marburg
Marburg and Ebola viruses Stephan Becker Philipps-Universität Marburg Filoviridae (order Mononegavirales) Matrix (VP40) Surface glycoprotein (GP) Lipid envelope Ribonucleoprotein complex (vrna, NP, VP35,
More informationR&D for potential vaccines for the Ebola virus
R&D for potential vaccines for the Ebola virus Update 4 March 2015 Roberto Bertollini MD MPH Chief Scientist and WHO Representative to the EU Gathering knowledge Since August 2014, series of consultations
More information(Public Health) Management of Ebola Disease. Aura Timen, MD, PhD. National Coordination Centre for Communicable Disease Control (LCI) CIb
(Public Health) Management of Ebola Disease Aura Timen, MD, PhD National Coordination Centre for Communicable Disease Control (LCI) CIb Het hoe,wat en wie van de LCI Everybody knows that pestilences have
More informationEmergency Medical Service General Order
Date of Issue: October 15, 2014 Effective Date: October 15, 2014 Plan Classification: Field Operations Commissioner of : No. Pages: 1 of 12 Rescinds: All previous directives Purpose: The U.S. Department
More informationGot Ebola? Kara Teresi, Alexandra Riedle,Anne Begley, and Victoria Torres
Got Ebola? Kara Teresi, Alexandra Riedle,Anne Begley, and Victoria Torres Ebola is being considered a Biosafety Level 4 Agent and is categorized as Category A Bioterrorism weapon in biological warfare
More informationEbola Virus disease in West Africa : challenges and lessons learned
Ebola Virus disease in West Africa : challenges and lessons learned Pr N. Shindo Dr S.C. Briand Pandemic and Epidemic Diseases Department WHO Geneva EVD outbreak in West Africa in Numbers From24 March
More informationEmerging Infectious Diseases: Update of Ebola Virus Disease
Emerging Infectious Diseases: Update of Ebola Virus Disease Assist Prof. Nasikarn Angkasekwinai, MD., MTM&H. Division of Infectious Diseases and Tropical Medicine Department of Medicine, Faculty of Medicine
More informationEbola Virus Disease (EVD) Preparedness Kit. To: All pharmacists From: Dr. Faith Stratton, Chief Medical Officer of Health Date: October 28, 2014
MEMO: Ebola Virus Disease (EVD) Preparedness Kit To: All pharmacists From: Dr. Faith Stratton, Chief Medical Officer of Health Date: October 28, 2014 This update is to provide information to pharmacists
More informationEbola outbreak in West Africa : Shift in paradigm
Ebola outbreak in West Africa : Shift in paradigm Dr S.C Briand, Director Pandemic and Epidemic Diseases department, WHO Geneva EVD West Africa: many "first time" Enormous epidemic in the affected countries
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS:
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationEbola Virus Disease: Pathophysiology and Clinical Aspects
Cronicon OPEN ACCESS MICROBIOLOGY Mini Review Ebola Virus Disease: Pathophysiology and Clinical Aspects Attapon Cheepsattayakorn 1,2 and Ruangrong Cheepsattayakorn 3 1 10 th Zonal Tuberculosis and Chest
More informationTraining Bulletin. Emergency Health Services Branch Ministry of Health and Long-Term Care. October 24, Issue Number version 2.
Training Bulletin Ebola Virus Disease October 24, 2014 Issue Number 114 - version 2.1 Emergency Health Services Branch Ministry of Health and Long-Term Care Training Bulletin, Issue Number 114 version
More informationSpecial Session on IHR and Ebola Virus Disease
Special Session on IHR and Ebola Virus Disease Roberta Andraghetti, WHO/PAHO/CHA/IR 12th Meeting Caribbean National Epidemiologists & Laboratory Directors Port of Spain, Trinidad and Tobago, 17-19 September
More informationEbola Virus Disease. West Africa Dr Sylvie Briand. Pandemic and Epidemic Diseases department
Ebola Virus Disease West Africa - 2014 Dr Sylvie Briand 1 Haemorrhagic fever Incubation period: 2 21 days Symptoms: start with fever, intense weakness, muscle pain, headache and sore throat. Followed by
More informationInfectious Disease/EBOLA Guidelines for the School Clinic
Infectious Disease/EBOLA Guidelines for the School Clinic Background: The procedures in the accompanying algorithm provide guidance on evaluation and management of individuals who present with possible
More informationEbola Q & A. # Question Answer Modified
Ebola Q & A # Question Answer Modified 1 Are U.S. hospitals ready to care for patients with Ebola virus disease (EVD)? Yes any U.S. hospital that is following CDC's infection control recommendations(http://www.cdc.gov/vhf/ebola/hcp/infectionprevention-and-control-recommendations.html)
More informationOur Job: Prevent dis-ease as well as disease
Our Job: Prevent dis-ease as well as disease 1 Kansas Ebola Virus Preparedness and Response Plan: Revised 15 October 2014 2 Background and Situation Update 3 West Africa (As of 12 October 2014) Total Cases
More informationThe Basics on Ebola and Textiles: Information for You and Your Healthcare Clients
The Basics on Ebola and Textiles: Information for You and Your Healthcare Clients The information below is compiled from information provided by the Centers for Disease Control (CDC). ARTA encourages members
More informationSince then, outbreaks have appeared sporadically in several African countries.
Ebola Virus Disease (also known as Ebola Hemorrhagic fever) is a severe, often fatal disease caused by infection with a species of Ebola virus. The first Ebola virus species was discovered in 1976 in what
More informationCategorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola
Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola This table, which is updated on a continuous basis, summarizes the data on drugs that are
More informationEBOLA VIRUS DISEASE FLIP BOOK TRAINING GOWHO GO PRE-DEPLOYMENT TRAINING
EBOLA VIRUS DISEASE FLIP BOOK TRAINING GOWHO GO PRE-DEPLOYMENT TRAINING WHO Library Cataloguing-in-Publication Data: Go training: package for Ebola pre-deployment. Contents: Participant handbook Ebola
More informationCalifornia Association for Medical Laboratory Technology. Distance Learning Program
California Association for Medical Laboratory Technology Distance Learning Program EBOLA VIRUS DISEASE Worldwide Implications Course # DL-013 The information in this course is from http://www.cdc.gove/vhf/ebola/healthcare-us/index.html
More informationEbola Virus Disease Update Pre-Council. October 21, 2014 Juan Ortiz, EMC Vinny Taneja, TCPH Director
Ebola Virus Disease Update Pre-Council October 21, 2014 Juan Ortiz, EMC Vinny Taneja, TCPH Director What is Ebola? Ebola is a viral disease, previously known as Ebola Hemorrhagic fever First found in 1976
More informationPatient safety in managing Ebola in resource-rich and poor settings
Patient safety in managing Ebola in resource-rich and poor settings Stephen Mepham Consultant in Microbiology and Infectious Diseases Royal Free London NHS Foundation Trust Colin Brown Infectious Diseases
More informationViral Haemorrhagic Fevers. Major Dan Burns Infectious Diseases Registrar
Viral Haemorrhagic Fevers Major Dan Burns Infectious Diseases Registrar 2 nd June 2018 Outline Viral Haemorrhagic Fevers West Africa Ebola Outbreak Kahoot.com Hit play Enter PIN 2966193 Viral Haemorrhagic
More informationEBOLA AND OTHER AFRICAN VIRAL HAEMORRHAGIC FEVERS
EBOLA AND OTHER AFRICAN VIRAL HAEMORRHAGIC FEVERS In response to the 2014 West African Ebola epidemic, last year s G-FINDER survey tracked funding for Ebola R&D for the first time, capturing FY2014 investments.
More informationDeadly but Curable: A Review on Potential Treatments for Ebola Haemorrhagic Fever
14 Review Article Deadly but Curable: A Review on Potential Treatments for Ebola Haemorrhagic Fever Bushra Shamim Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi, India
More informationEbola: Working Toward Treatments and Vaccines
Claire Sykes and Miriam Reisman The deadly and highly infectious Ebola virus was discovered in 1976 in Yambuku in the Democratic Republic of Congo, 60 miles from the river after which it was named. 1 But
More informationFrom research to large-scale use
Accelerating access to Ebola vaccines From research to large-scale use Dr Marie-Paule Kieny Assistant Director General HIS 1 Number of cases Ebola response roadmap: Situation report 3 December 2014 Sierra
More informationEbola Virus Disease Q&As for Nova Scotia Health Care Workers
EBOLA VIRUS DISEASE Ebola virus disease is a severe disease that causes hemorrhagic fever in humans and animals. While the likelihood of a case presenting in Nova Scotia is very low, the province s health
More informationEbola Vaccines and Treatments
Ebola Vaccines and Treatments Current Prevention and Treatment Isolation of cases Stringent infection control Contact tracing Surveillance Risk communication Treatment options limited Supportive therapy
More informationZaire Ebola Virus. Nucleoprotein (np) gene. 150 tests. Techne qpcr test. Quantification of Zaire Ebola Virus genomes Advanced kit handbook HB10.01.
Techne qpcr test Zaire Ebola Virus Nucleoprotein (np) gene 150 tests For general laboratory and research use only 1 Introduction to Zaire Ebola Virus Ebola viruses are the causative agents for a severe,
More informationCategorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola
Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola This table, which is updated on a continuous basis, summarizes the data on drugs that are
More informationEBOLA AND PREPAREDNESS AT DENVER HEALTH. Amber Miller, MSN, RN, CIC, CSPDT, Infection Prevention Manager Denver Health
EBOLA AND PREPAREDNESS AT DENVER HEALTH Amber Miller, MSN, RN, CIC, CSPDT, Infection Prevention Manager Denver Health Denver Health and Hospital September 18, 2015 Agenda Background on Ebola Overview of
More informationChicago Ebola Preparedness Update. Suzet McKinney, DrPH, MPH, Deputy Commissioner Stephanie Black, MD, MSc, Medical Director March 18, 2015
Chicago Ebola Preparedness Update Suzet McKinney, DrPH, MPH, Deputy Commissioner Stephanie Black, MD, MSc, Medical Director March 18, 2015 Agenda Ebola Overview Crisis in West Africa Symptoms and transmission
More informationWebCast For Continuing Education
WebCast For Continuing Education 2016 Northern California EMS, Inc. Engineer Bill Bogenreif. 1 Ebola Virus Disease Update 5/4/2016 Eric M. Rudnick, MD, FACEP,FAAEM Northern California EMS, Inc. Engineer
More informationEfficacy trials of Lassa Therapeutics: endpoints, trial design, site selection
Efficacy trials of Lassa Therapeutics: endpoints, trial design, site selection WHO Workshop Final Report April 25, 2018 INSERM, Paris, France Table of contents TABLE OF CONTENTS 1 1. INTRODUCTION 2 2.
More informationProgress of vaccine and drug development for Ebola preparedness
Review article CLINICAL EXPERIMENTAL VACCINE RESEARCH Progress of vaccine and drug development for Ebola preparedness Clin Exp Vaccine Res 2015;4:11-16 http://dx.doi.org/10.7774/cevr.2015.4.1.11 pissn
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More information1 - General FAQs about the Ebola virus (pages 1-3)
EBOLA FAQs This document contains three sections of FAQs: 1 - General FAQs about the Ebola virus (pages 1-3) 2 - FAQ for staff who may be meeting guests arriving from infected areas who ve been invited
More informationWhat this is for: Guidance keeping workers safe while handling inquiries and responding to patients with suspected Ebola symptoms.
Interim Guidance for Emergency Medical Services (EMS) Systems and 9-1-1 Public Safety Answering Points (PSAPs) for Management of Patients with Known or Suspected Ebola Virus Disease in the United States
More informationwww.newsflashenglish.com The 4 page 60 minute ESL British English lesson 25/08/14 Today, let s talk about the deadly Ebola threat that is spreading itself across Western Africa. Every day many people are
More informationEbola Convalescent Plasma: Considerations for future outbreaks
Ebola Convalescent Plasma: Considerations for future outbreaks Based on EVD-001 and -002 Monrovia; Liberia Nov 2014-Jan 2015 For IPFA s Workshop on Improving Access to Plasma and Plasma Products in the
More informationWHO-MSD Collaboration to Bring an Ebola Vaccine to the Populations in Need
WHO-MSD Collaboration to Bring an Ebola Vaccine to the Populations in Need Jules Millogo, MD, MSc Director, Public Health Partnerships Merck & Co, Inc. North Wales, PA, USA V920: rvsvδg-zebov-gp Vaccine
More informationBackgrounders. Ebola Virus. Author: Danielle Renwick, Copy Editor October 24, Introduction
1 of 5 31.10.2014 15:27 Backgrounders Ebola Virus Author: Danielle Renwick, Copy Editor October 24, 2014 Introduction The Ebola virus disease, formerly called the Ebola hemorrhagic fever, was first identified
More informationTown Hall: Ebola Virus
Town Hall: Ebola Virus An outbreak of Ebola virus disease (EVD) has affected people in four countries in Western Africa (Guinea, Liberia, Sierra Leone and Nigeria) since its first detection in March of
More informationAnnouncements. Please mute your phones and DO NOT place us on hold. Press *6 to mute/unmute your phone.
1 Announcements Register for the Epi-Tech Trainings: 1. Log-on or Request log-on ID/password: https://tiny.army.mil/r/zb8a/cme 2. Register for Epi-Tech Surveillance Training: https://tiny.army.mil/r/leaid/epitechfy15
More informationCDC Support for Exit Screening and Lessons Learned for Preparedness
CDC Support for Exit Screening and Lessons Learned for Preparedness Andrew Demma, MS International Assistance Lead Global Migration Task Force Centers for Disease Control and Prevention National Center
More informationA surveillance of Ebola outbreak at Télimélé, Guinea Conakry 2014
A surveillance of Ebola outbreak at Télimélé, Guinea Conakry 2014 Jean Marie Vianney Namahoro Postgraduate student Stellenbosch University Fakulteit Geneeskunde en Gesondheidswetenskappe Faculty of Medicine
More informationIntroduction. That warning is not from a fringe news organization that thrives on spreading false information and fear.
Disclaimer The material herein is accurate to the best of the author s knowledge. However, the author s opinions may change. The reader is encouraged to verify the status of those opinions. This publication
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationIHR AND AIRPORT SCREENING DURING A PUBLIC HEALTH EMERGENCY OF INTERNATIONAL CONCERN (PHEIC)
AIRPORT SCREENING Kimberly Rogers Quarantine and Border Health Services Branch Division of Global Migration and Quarantine U.S. Centers for Disease Control and Prevention October 13, 2015 OBJECTIVES Understand
More informationEBOLA IS IN NEW YORK CITY
OCTOBER 28, 2014 EBOLA IS IN NEW YORK CITY SHOULD WE BE WORRIED? HEALTHCARE TEAM A CALL WITH Dr. Jeffrey Shaman Shaman Research Group LEGAL DISCLAIMER Hedgeye Risk Management is a registered investment
More informationOff Label or On Target? The Ethics of Investigational and Compassionate Uses
Off Label or On Target? The Ethics of Investigational and Compassionate Uses G. Kevin Donovan, MD, MA Director, Pellegrino Center for Clinical Bioethics Professor of Pediatrics Georgetown University School
More informationLassa fever A neglected disease in Africa Who are the patients and what are their outcomes?
Lassa fever A neglected disease in Africa Who are the patients and what are their outcomes? A Dahmane, R Zachariah, R Van den Bergh, T Reid, Y Nzomukunda, M Allaouna,P Alders,M Van Herp,R Souya, Dr Grant,
More informationEbola outbreak in Western Africa 2014: what is going on with Ebola virus?
Review article CLINICAL EXPERIMENTAL VACCINE RESEARCH Ebola outbreak in Western Africa 2014: what is going on with Ebola virus? Clin Exp Vaccine Res 2015;4:17-22 http://dx.doi.org/10.7774/cevr.2015.4.1.17
More informationSudan Ebola Virus. genesig Standard Kit. Nucleoprotein (np) gene. 150 tests. Primerdesign Ltd. For general laboratory and research use only
TM Primerdesign Ltd Sudan Ebola Virus Nucleoprotein (np) gene genesig Standard Kit 150 tests For general laboratory and research use only 1 Introduction to Sudan Ebola Virus Ebola viruses are the causative
More informationJacob Mufunda Head of WHO Country Office Mozambique. 27 September 2014
College Guest Lecture: Recent personal experiences on Ebola in Sierra Leone West Africa Jacob Mufunda Head of WHO Country Office Mozambique 27 September 2014 Outline of presentation 1. Ebola disease outbreak
More informationInterim Ebola Protocol: Inmate Screening and Management
Federal Bureau of Prisons Interim Ebola Protocol: Inmate Screening and Management December 5, 2014 This protocol is made available to the public for informational purposes only. The Federal Bureau of Prisons
More informationGuidelines on the quality, safety and efficacy of Ebola vaccines
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 Guidelines on the quality, safety and efficacy of Ebola vaccines World Health Organization 2017 All rights reserved.
More informationEbola virus (2014 outbreak)
TM Primerdesign Ltd Ebola virus (2014 outbreak) Nucleoprotein (NP) gene genesig Standard Kit 150 tests For general laboratory and research use only 1 Introduction to Ebola virus (2014 outbreak) Ebola virus
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationEbola virus disease outbreak in western Africa
Action Plan Strategic Objectives 6. Promote innovation and research on new drugs International surveillance networks and information sharing on promising research Active role in research for governments
More informationTime Efficiencies to Be Gained from Platform Approaches to Drug Development
Time Efficiencies to Be Gained from Platform Approaches to Drug Development Monday, July 27th, 2015 Room 100 National Academy of Sciences Keck Center 500 5 th Street NW, Washington DC 20001 Meeting Description
More informationEBOLA HAEMORRHAGIC FEVER VIRUS: PATHOGENESIS, IMMUNE RESPONSES, POTENTIAL PREVENTION
FOLIA MEDICA CRACOVIENSIA Vol. LIV, 3, 2014: 39 48 PL ISSN 0015-5616 39 Janusz Marcinkiewicz 1, Krzysztof Bryniarski 1, Katarzyna Nazimek 1 EBOLA HAEMORRHAGIC FEVER VIRUS: PATHOGENESIS, IMMUNE RESPONSES,
More informationEbola Response: A Summary of Field Work Project
The University of San Francisco USF Scholarship: a digital repository @ Gleeson Library Geschke Center Master's Projects and Capstones Theses, Dissertations, Capstones and Projects Winter 12-12-2014 Ebola
More informationPage 1 of 6 Interim Guidance for Emergency Medical Services (EMS) Systems and 9-1-1 Public Safety Answering Points (PSAPs) for Management of Patients Who Present With Possible Ebola Virus Disease in the
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector
More informationRole of DIAGNOSTICS in BIOPREPAREDNESS Mark Miller, MD Chief Medical Officer biomerieux
Role of DIAGNOSTICS in BIOPREPAREDNESS Mark Miller, MD Chief Medical Officer biomerieux 29.09.2016 IMI Stakeholder Forum 2016 Brussels, Belgium A distant history lesson Those who cannot remember the past
More informationSurveillance strategy during Phase 3 of the Ebola response
EMERGENCY GUIDANCE Surveillance strategy during Phase 3 of the Ebola response 5 November 2015 World Health Organization 2015. All rights reserved. The designations employed and the presentation of the
More informationWHO announces Ebola milestone as Guinea outbreak ends (Update) 29 December 2015
WHO announces Ebola milestone as Guinea outbreak ends (Update) 29 December 2015 As world health watchdogs struggled to respond, the death toll mounted at a dizzying rate, igniting fears in Europe and elsewhere
More informationMouse Models for Filovirus Infections
Viruses 2012, 4, 1477-1508; doi:10.3390/v4091477 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Mouse Models for Filovirus Infections Steven B. Bradfute 1, *, Kelly L. Warfield
More informationZaire Ebola Virus. genesig Advanced Kit. Nucleoprotein (np) gene. 150 tests. Primerdesign Ltd. For general laboratory and research use only
TM Primerdesign Ltd Zaire Ebola Virus Nucleoprotein (np) gene genesig Advanced Kit 150 tests For general laboratory and research use only 1 Introduction to Zaire Ebola Virus Ebola viruses are the causative
More informationThe largest outbreak of EVD in history began in December 2013 in
The new england journal of medicine brief report Clinical Care of Two Patients with Ebola Virus Disease in the United States G. Marshall Lyon, M.D., M.M.Sc., Aneesh K. Mehta, M.D., Jay B. Varkey, M.D.,
More informationTaï Forest Ebola Virus
PCRmax Ltd TM qpcr test Taï Forest Ebola Virus Nucleoprotein (np) gene 150 tests For general laboratory and research use only 1 Introduction to Taï Forest Ebola Virus Ebola viruses are the causative agents
More informationDiagnostics: Learning from successful experiences which made it to market. Mark Miller, MD Chief Medical Officer biomérieux France
Diagnostics: Learning from successful experiences which made it to market Mark Miller, MD Chief Medical Officer biomérieux France Diagnostics: Learning from unsuccessful experiences which almost made it
More informationName: Ebola Epidemic: Student Worksheet
Ebola Epidemic: Student Worksheet Ebola Virus Disease (EVD), also known as Ebola hemorrhagic fever, is a rare and deadly disease. The 2014 Ebola epidemic is the largest in history, affecting multiple countries
More informationNee-Kofi Mould-Millman, MD. Assistant Professor, Dept of Emergency Medicine Senior Investigator, Center for Global Health
Nee-Kofi Mould-Millman, MD Assistant Professor, Dept of Emergency Medicine Senior Investigator, Center for Global Health No conflicts of interest No financial disclosures 1) To understand pathogenesis
More informationLogistics. Registration for free continuing education (CE) hours or certificate of attendance through TRAIN at:
. DSHS Grand Rounds Logistics Registration for free continuing education (CE) hours or certificate of attendance through TRAIN at: https://tx.train.org Streamlined registration for individuals not requesting
More informationIntravenous Immunoglobulin
Intravenous Immunoglobulin 1 / 7 2 / 7 3 / 7 Intravenous Immunoglobulin This therapy can help people with weakened immune systems or other diseases fight off infections. Some of the diseases that can treat
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: The PREVAIL II Writing Group. A randomized, controlled trial of ZMapp
More informationLicenced Ebola Vaccine
The Market Shaping Goal Shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices for developing countries. Supply and Procurement Roadmap Licenced
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: WHO Ebola Response Team. Ebola virus disease among children
More informationAir ambulance evacuations in the Ebola crisis context
Air ambulance evacuations in the Ebola crisis context Dr Arnaud DEROSSI Regional Medical Director, Assistance & Global Medical Transport Still a Hot topic although promising trends Challenge: Not only
More informationEbola is a rare and potentially deadly
Ebola in the United States: Management considerations during pregnancy Nearly 100% of pregnant women infected with Ebola die. Clinicians should be aware of this statistic and familiar with general, as
More informationPre-existing anti-viral vector antibodies in gene therapy
Pre-existing anti-viral vector antibodies in gene therapy Impact on assays, study conduct and data interpretation Mark N Milton, Executive Director DMPK-Bx, Novartis AAPS NBC, May 2016 Gene Therapy Treatment
More informationFailure to Collide Ebola and Modern Medicine, 2014
Failure to Collide Ebola and Modern Medicine, 2014 Paul Farmer, MD, PhD Harvard Medical School Brigham and Women s Hospital Partners In Health Kapuscinski Development Lecture King s College London April
More information